Objectives: Leishmania parasites reside within macrophages and the direct target of antileishmanial drugs is therefore intracellular. We aimed to characterize the intracellular PBMC miltefosine kinetics by developing a population pharmacokinetic (PK) model simultaneously describing plasma and intracellular PBMC pharmacokinetics. Furthermore, we explored exposure-response relationships and simulated alternative dosing regimens.
Introduction
Leishmania are protozoan parasites that cause the tropical disease leishmaniasis, which can result in diverse clinical manifestations, such as systemic infection (visceral leishmaniasis) or the skin lesions of cutaneous leishmaniasis. The parasites primarily reside and replicate in macrophages during infection of humans or other mammalian hosts. Hence, the direct target of antileishmanial drugs is inside macrophages, highlighting the relevance of the intracellular pharmacokinetics of these drugs. 1 Miltefosine is currently the only registered oral drug for treatment of leishmaniasis. Several hypotheses exist for the mechanisms of action of miltefosine, including disturbance of lipid-dependent cell signalling and induction of mitochondrial dysfunction and apoptosis, which require macrophage membrane sequestering or cell entry of miltefosine. 2 A large portion (57%) of total miltefosine has been found to be sequestered in the Caco-2 cell membrane after in vitro incubation, whereas only 7% was transported across the membrane. transported towards the inner leaflet by both passive and active transport mechanisms in the clinically observed range of miltefosine plasma concentrations. 3, 4 Interindividual variability in saturation of the active inward translocation of miltefosine could potentially result in between-subject variability (BSV) in intracellular exposure of parasites to this drug.
Miltefosine pharmacokinetics have, until our recent study, only been described in plasma, in both cutaneous and visceral leishmaniasis patients. [5] [6] [7] Children with visceral leishmaniasis were found to be underexposed to miltefosine in comparison with adults when treated with the conventional linear, 28 day, 2.5 mg/kg daily dosing regimen. Furthermore, a relationship between miltefosine exposure and probability of final treatment cure was established in visceral leishmaniasis. 7 An allometric dosing regimen based on fatfree mass (FFM) was proposed to increase miltefosine exposure in children to adult levels, in order to increase the probability of cure. 6 We previously conducted a pharmacokinetic (PK) clinical trial to compare the pharmacokinetics of miltefosine in paediatric and adult cutaneous leishmaniasis patients in Colombia, the results of which have recently been published. 1 The non-compartmental PK analysis (NCA) in that report contains the first known description of intracellular miltefosine exposure in PBMCs. Intracellular PBMC miltefosine steady-state concentrations were found to be around 2-fold higher than plasma concentrations, which could be clinically relevant with regard to miltefosine's intracellular mode of action. Lower miltefosine exposure in paediatric compared with adult patients was confirmed, both in plasma and intracellularly, but no exposure-response relationship could be discerned. 1 The objective of the present study was to develop a population PK model with the data of the aforementioned study, 1 describing the kinetics of intracellular distribution of miltefosine in PBMCs by simultaneous modelling of plasma and intracellular PBMC concentrations. Using a non-linear mixed effects modelling approach, miltefosine exposure can be more accurately described than with NCA, particularly with the sparse sampling scheme achievable in young children. 8 Additionally, we explored the exposure-response relationship between plasma and intracellular PBMC exposure and treatment outcome and we simulated an allometric dosing regimen in both children and adults using the developed population PK model.
Patients and methods

Study population, PK sampling and bioanalysis
Data for this model-based analysis originated from an open-label clinical trial investigating the pharmacokinetics of 28 day 1.8-2.5 mg/kg daily miltefosine monotherapy for the treatment of cutaneous leishmaniasis patients (registered as NCT01462500). The non-compartmental PK data, toxicity and treatment outcomes have been published previously. 1 Sixty patients (30 adults and 30 children) were treated in two outpatient clinical facilities in Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM) in Cali and Tumaco, Colombia.
1 Cure was defined as complete reepithelialization and absence of inflammatory signs for all lesions at the end of a 6 month follow-up period.
Plasma and PBMC samples were obtained from heparin anticoagulated peripheral blood collected pre-dose, after 1, 14 and 28 days of treatment, and during the follow-up period on day 60, 90, 120 and 210 after start of treatment. For PBMC isolation, the blood sample was diluted in PBS and placed over a Ficoll gradient. 9 In short, the mononuclear leucocyte layer was isolated after a 15 min 400 g centrifugation step at room temperature and washed twice with PBS. After an 800 g centrifugation step, the supernatant was removed and pellets were stored at #80 C. Plasma and PBMC samples were transported to the bioanalytical laboratory and stored at #20 C until analysis. Analysis was performed with LC-MS/MS. 1, 9, 10 Intracellular PBMC concentrations were calculated as described previously using the PBMC cell count and average cell volume. 9, 11 PK samples were available for 59 patients. Seven patients were excluded from the population PK analysis owing to potential nonadherence based on their PK profiles (.40% miltefosine decrease concentration during treatment). 1 One additional patient was excluded owing to missing dosing data, bringing the number of patients included in the population PK model to 51. Of these, two patients were lost to follow-up. As treatment outcome could not be evaluated for these patients, data from 49 patients were included in the exposure-response exploratory analysis.
Ethics
Ethics approval was obtained from the institutional ethics review board of CIDEIM and the Colombian National Institute for Food and Drug Safety (INVIMA). Written informed consent was obtained from each patient. Written informed consent was provided by the legal guardians of paediatric patients, and children .7 years old provided written informed assent.
Population PK analysis
Data management was performed in R (version 3.1.2) and Excel (Office 2007). Non-linear mixed effects modelling was performed with NONMEM (version 7.3) using a first-order conditional estimation procedure with interaction between interindividual variability and residual error components. Pirana (version 2.8.1) was used as an interface between NONMEM, Perlspeaks-NONMEM (PsN, version 3.4.2), R and the R-package Xpose (version 4.5.3) to evaluate model performance.
Minimization of the objective function value (OFV, minus twice the log likelihood) was used as a basic evaluation method to guide selection of a structural, stochastic and covariate model (selection criteria DOFV!3.84, P,0.05). Goodness of fit and predictive performance of the models were evaluated by graphical methods and visual predictive check (VPC) based on 1000 simulated replicates, respectively. A bootstrap (1000 samples) was performed to assess precision and reliability of the final parameter estimates. Shrinkage of empirical Bayes estimates and residual error components were evaluated.
Structural model
Population PK models were first evaluated using miltefosine plasma data only to identify the best structural model. A previously developed open two-compartment model with first-order absorption and linear elimination from the central compartment was taken as reference model from which further structural models were developed. 5, 6 Subsequently, PBMC data were added to the data set to link intracellular to plasma data using an effect compartment strategy. 12, 13 All final parameters for the structural model with plasma and PBMC data were estimated in a simultaneous fit.
The primary PK parameters estimated were CL (elimination clearance or intercompartmental clearance) and V. Both CL and V were expressed relative to bioavailability because the absolute bioavailability of miltefosine is unknown. Owing to limited sampling per dosing interval, the absorption rate (k a ) was fixed at 9.6 day #1 , based on previously reported values. 7 Stochastic model BSV in PK parameters was estimated with an exponential model. Residual variability was modelled with separate proportional errors for plasma and intracellular PBMC data as more variability is expected in PBMC compared with plasma separation.
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Covariate model
Covariate selection was done using forward inclusion and backward elimination with the final structural PK model, with selection criteria of DOFV!3.84 (P,0.05) and !6.64 (P,0.01), respectively. Body weight and FFM were evaluated as covariates on V and CL. The population estimates for CL and V were scaled to a standard weight of 70 kg or FFM of 53 kg to make results comparable to previously published studies. 6, 7 An allometric power function was used with a power of 0.75 for CL and 1 for V (representing linear scaling), based on a previously published population PK model. 6 FFM was initially calculated as described in Equation 1 where 
Owing to the large proportion of paediatric patients in this study, an age maturation component in FFM calculation was introduced (Equations 2 and 3), 15 estimating FFM with a sigmoid hyperbolic function asymptoting towards the predicted adult FFM described in Equation 1, with age and gender as additional covariates. Model-based exposure estimates and exploring exposure-response relationships AUC model-based estimates were calculated for each individual included in the population PK model by integrating the area under the individual modelbased predicted miltefosine concentrations over time until day 28 of treatment (AUC D0-D28 ) and infinity (AUC 0-1 ), both in plasma (AUC PL ) and intracellularly in PBMCs (AUC IC ). Of the 51 patients included, Leishmania strains were isolated from 37 patients, of which 89% corresponded to Leishmania (Viannia) panamensis. IC 50 values were not determined in this study population. The median ex vivo IC 50 of 1.9 mg/L found in clinical strains isolated from 11 patients from the same endemic region as participants from the present study, infected with L.V. panamensis, 16 was used to calculate the time.IC 50 (total time the individual model-based predicted miltefosine concentration was above IC 50 , in days) and AUC.IC 50 (integration of area under individual model-based predicted concentration above IC 50 , in mgÁday/L).
The exposure-response relationships based on model-based estimates were explored with a logistic regression analysis in R. The logistic regression analysis was performed on a binary outcome (0"failure, 1"cure) as described in Equation 4 for AUC PL, D0-D28 (in mgÁday/L) as an example exposure variable. k i is the log odds of cure for the i th individual, k b represents the baseline log odds of cure and h 1 describes the drug effect.
Subsequently, k i was converted to probability of cure for the i th individual (p i , Equation 5 ).
Additional independent covariates available (baseline lesion size, lesion duration before treatment, number of lesions, sex, ethnicity and age) were evaluated as additional predictor variable next to the exposure variable, as described in Equation 6 with h 2 describing the effect of the covariate (COV) on the log odds of cure for the i th individual.
Previously determined individual susceptibility data of isolated strains 1 based on the reduction of intracellular parasite burden at a concentration of 16 lM miltefosine ex vivo, were also evaluated as covariate in addition to drug effect as described in Equation 6. For 13/49 patients included in the exposure-response exploratory analysis, susceptibility data were unavailable and thus the median value was imputed.
Simulations of allometric dosing regimen
An allometric dose of miltefosine has previously been proposed for children with visceral leishmaniasis: a more optimal dosing schedule based on FFM, not linearly scaled but with a power exponent of 0.75, following allometric principles. 6 Drug exposure after allometric dosing was compared with conventional linear 2.5 mg/kg/day dosing. PK curves were simulated (n"1000) for patients with similar anthropometric characteristics as the subjects in the original data set. The allometric dose was based on FFM as calculated with Equations 2 and 3. 15 As an example, using these study participants' anthropometric characteristics, the allometric dose of subjects between 4 and 7 years old would lie between 2.8 and 3.2 mg/kg/day, as opposed to the standard 2.5 mg/kg dose. The 2.5 mg/kg/day dosing regimen and allometric dosing regimen were both rounded to the nearest 10 mg capsule, based on available formulations (10 or 50 mg).
Results
Patient and sample inclusion in population PK model
Demographic characteristics of the 51 study participants included in the population PK analysis are described in Table 1 . Intracellular PBMC miltefosine concentrations on day 90 and afterwards were excluded from PK analysis because miltefosine concentrations for .80% of these samples were below the lower limit of quantification (,LLOQ). The drug concentration in one plasma sample was ,LLOQ and was therefore excluded. Two PBMC and two plasma samples were excluded owing to the high absolute conditionally weighted residuals (CWRES.4). Finally, concentration data from 339 plasma and 194 PBMC samples were included in the population PK model.
Miltefosine population pharmacokinetics in plasma and intracellularly in PBMCs
Intracellular PBMC distribution appeared to be delayed, because the median intracellular-to-plasma ratio increased from 1.2, after the first day, to 2.9 after 28 days of treatment. Variability in observed intracellular PBMC concentrations was larger [relative standard deviation (RSD) 91%] compared with plasma concentrations (RSD 33%). This may partially be explained by higher variability in PBMC bioanalysis but might also be indicative of larger variability in miltefosine uptake between patients.
A three-compartment model significantly improved the fit (DOFV #232) compared with the previously developed twocompartment model, 6, 7 as the latter overestimated concentrations on day 28 and 120. The model that best described the intracellular PBMC data was found to be miltefosine distribution to an intracellular PBMC effect compartment without mass transfer Kip et al. from the central compartment. This distribution was described by a steady-state intracellular-to-plasma ratio (R IC:P ) plus intracellular distribution rate constant between plasma and intracellular PBMC compartment (k P-IC ) (Figure 1, Equation 7 , where A IC represents the amount of drug in the intracellular PBMC compartment, A C the amount of drug in the central compartment and V c the volume of distribution of the central compartment).
Final parameter estimates are presented in Table 2 . The R IC:P was found to be 2.17 (95% CI 1.98-2.39), indicating an $2-fold higher intracellular PBMC miltefosine concentration compared with plasma. The delayed distribution was described with the k P-IC of 1.23 (95% CI 0.94-1.58) day
#1
. The mean of the individual estimates of R IC:P and k P-IC were comparable between adults and children (R IC:P of 2.3 and 2.2, and k P-IC of 1.2 and 1.3, respectively).
Allometric scaling of V c and CL by FFM significantly improved the fit compared with scaling by total body weight (DOFV #12). Inclusion of the maturation component in FFM calculation improved the model significantly (DOFV #7.5). Other evaluated covariates did not improve the model.
Standard goodness-of-fit plots ( Figures S1 and S2 , available as Supplementary data at JAC Online) indicated no obvious deviations, except for a slight overprediction of the highest plasma concentrations after inclusion of intracellular PBMC data in the final model. The VPC of the final population PK model showed good predictive performance of the model compared with the observations (Figure 2) .
Using the final population parameter estimates, the plasma elimination half-lives were calculated to be 3.5 days, 7.6 days and a terminal elimination half-life of 51 days. Secondary PK parameters related to exposure were calculated from individual exposure estimates of the 51 patients in the final model (Table 3) . Plasma and intracellular PBMC exposure variables were significantly higher for adults compared with children.
Exploration of exposure-response relationships
Of the 49 patients included in the exposure-response analysis, 5 paediatric patients presented with treatment failure. Exploration of the contribution of individual exposure variables to treatment outcome indicated a significant influence of all exposure values (both plasma and intracellular PBMC exposure) on probability of cure, except time.IC 50 for intracellular PBMC miltefosine concentrations (Table 4) . As an example, each 10 mgÁday/L increase in AUC PL, D0-D28 resulted in an increased OR for cure of 1.64 (95% CI 1.18-3.09, k B "#23.6). Probability of failure (calculated with Equations 4 and 5) increased from 0.06% to 22.6% for a decrease in AUC PL, D0-D28 from the median value 623 mgÁday/L to 500 mgÁday/L. Based on this analysis, the AUC PL, D0-D28 should exceed 535 mgÁday/L to reach .95% probability of cure. The AUC PL, D0-D28 of all adults in our analysis exceeded this potential PK target, but 12/28 children (43%) did not attain this value. Probability of clinical cure as a function of the AUC PL, D0-D28 is depicted in Figure 3 . The wide CIs reflect the small number of patients that failed treatment.
Baseline lesion size, number of lesions, time of lesion duration prior to treatment, age, gender and isolated strain susceptibility data were not significantly associated with log odds of cure in the multivariate analysis, on top of miltefosine exposure.
Allometric dosing simulation
AUC PL, D0-D28 values following simulations of linear and allometric dosing regimens are provided in Table 5 . Allometric dosing of Population PK of plasma and intracellular miltefosine JAC miltefosine resulted in similar exposure levels between children and adults in this patient cohort. Simulating allometric dosing, the fraction of children not attaining the proposed AUC PL, D0-D28 threshold of 535 mgÁday/L was an order of magnitude lower at 1.8%, compared with 18.3% after simulating the linear dose.
Discussion
We report a compartmental population PK model characterizing the pharmacokinetics of miltefosine in plasma and PBMCs and, based on this model, describe the population pharmacokinetics of miltefosine in adults and children with cutaneous leishmaniasis. Due to absence of sampling in the absorption phase, this was fixed to a previously established value of 9.6. c Estimates are provided for patients with an FFM of 53 kg.
Kip et al.
The observed plasma and intracellular PBMC miltefosine concentrations were well described and predicted by the population PK model. PK parameter estimates of the final model were in line with values previously reported. [5] [6] [7] The V c was smaller than previously documented (28.5 L versus 38.5-40.1 L), due to the inclusion of a second peripheral compartment. [5] [6] [7] The two peripheral compartments were required to accurately describe the observed multiphasic elimination phase. Triphasic elimination has never been observed previously for miltefosine 5 and was possibly influenced by denser sampling in the first 3 months after treatment in the current study.
Implementation of k P-IC was required to characterize the delay in intracellular PBMC miltefosine distribution. In Caco-2 cells, only 6.8% of miltefosine was transported across cells after a 3 h incubation, whereas 57% accumulated in the membranes, from which intracellular release was slow (5% in 24 h). 3 Inward translocation of miltefosine within the cellular membrane was found in vitro to be partially dependent on active saturable transport. 3, 4 These sequential processes could hypothetically explain the delayed intracellular PBMC miltefosine distribution, potentially leading to variability in the extent of intracellular PBMC distribution amongst patients. Redistribution of miltefosine during washing of the cells upon harvesting is not expected to have affected the intracellular concentrations, because all washing steps were short, under cold conditions, whereas miltefosine's lipophilicity probably favours the cell membrane.
Compared with the previously reported model-based AUC PL, D0-D28 estimate of $500 mgÁday/L for Indian paediatric visceral leishmaniasis patients, 6 the AUC PL, D0-D28 estimate for paediatric patients in this study was 9% higher (545 mgÁday/L). As this is a relatively small difference, large variations between these two patient populations in PK characteristics such as metabolism and distribution of miltefosine are not expected, although these could Population PK of plasma and intracellular miltefosine JAC have been anticipated due to differences in clinical presentation (e.g. altered liver physiology in visceral but not cutaneous leishmaniasis).
Although the clinical PK trial from which the current data originated was not powered to evaluate efficacy, our results might provide a potential miltefosine exposure target in treatment of cutaneous leishmaniasis. In contrast to the previous multivariate analysis using NCA PK estimates, 1 population PK model-based estimates of plasma and intracellular PBMC miltefosine exposure were significantly associated with probability of cure. Differences in results between these methodologies could be caused by this trial's restricted sampling scheme designed to comply with ethical requirements of sampling in children. The NCA PK estimates from the previous analysis therefore underestimate the AUC PL, D0-D28 (e.g. for children, 456+100 mgÁday/L compared with the 545+64 mgÁday/L model-based estimate). Differences in results between these methodologies could not be explained by exclusion of the eight potentially non-adherent patients in the population PK model, as the NCA exposure-response relation remained not significant when excluding these patients (data not shown).
In this study, both plasma and intracellular PBMC miltefosine exposure were significantly related to probability of cure, which can be expected as plasma and intracellular PBMC concentrations are highly correlated. In future clinical studies, intracellular PBMC exposure could potentially be predicted from plasma PK using the here-developed population PK model. It might be valuable to relate intracellular PK to individual IC 50 (or IC 90 ) values from clinical parasite strains to calculate individual time.IC 50 and AUC.IC 50 exposure variables. Exploration of these intracellular PBMC PK/pharmacodynamic (PD) relationships could aid in understanding the contribution of Leishmania drug susceptibility to individual therapeutic outcome.
Ex vivo IC 50 values of previously isolated clinical strains of L.V. panamensis varied widely with a median (range) of 1.9 (0.53-13) mg/L. 16 The median 1.9 mg/L IC 50 value used in the current analysis provides a first approximation (to our knowledge) that can be evaluated and adjusted based on future drug susceptibility studies. In a sensitivity analysis increasing IC 50 values up to 13 mg/L, there were no profound differences in the PK/PD relationship, except that time.IC 50,IC, 0-1 was a significant predictor of cure above a certain level (data not shown). We aimed to capture the variability in susceptibility by including individual miltefosine susceptibility scores (% parasite load reduction after ex vivo exposure to 16 lM) 16 as a covariate effect on probability of cure in addition to drug exposure. No significant effect was identified, possibly due to the small sample size and unavailable susceptibility data for Leishmania strains that were not isolated from two out of five patients who failed treatment. Drug susceptibility values are influenced by a multitude of factors, including type of host cell. 17 It Kip et al.
should be noted that the current analysis used values derived from studies using human macrophages differentiated from U937 cells. Lastly, model-based simulations showed that an allometric dose regimen would result in a higher probability of reaching the proposed AUC PL, D0-D28 threshold of 535 mgÁday/L for children. The safety of this allometric regimen is currently being evaluated in East Africa (NCT02431143) and Bangladesh (NCT02193022). Differences in simulated (82%, Table 4 ) versus observed target attainment (57%) in children after conventional dosing could be explained by the lower administered daily dose of 2.3 mg/kg (Table 1 , range 2.0-2.5 mg/kg) compared with the simulated 2.5 mg/kg. 1 Additionally, the 90%-100% range of adherence to treatment for patients in this study 1 could also have contributed to lower observed target attainment compared with simulations with 100% adherence.
In conclusion, we developed a population PK model, which in addition to plasma miltefosine pharmacokinetics also describes the intracellular kinetics in PBMCs, characterizing miltefosine exposure in a compartment that is a closer approximation of miltefosine's in vivo target site of action. In the future, the model can be used in predicting individual intracellular PBMC concentration data, which can subsequently be related to individual Leishmania drug susceptibility to identify its impact on therapeutic outcome. In the here-presented exploratory exposure-response analysis, both plasma and intracellular PBMC miltefosine exposure parameters were significantly associated with probability of cure. A 535 mgÁday/L AUC PL, D0-D28 threshold could be proposed from our analysis as a putative PK target; however, its validity should be evaluated in a larger cohort of patients. The developed model can be exploited for analyses of PK/PD relationships in these future trials.
